Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients by Massimiliano Fabbiani et al.
RESEARCH ARTICLE Open Access
Single tablet regimens are associated with
reduced Efavirenz withdrawal in antiretroviral
therapy naïve or switching for simplification
HIV-infected patients
Massimiliano Fabbiani1, Mauro Zaccarelli2,5*, Pierfrancesco Grima3, Mattia Prosperi4, Iuri Fanti1, Manuela Colafigli1,
Alessandro D’Avino1, Annalisa Mondi1, Alberto Borghetti1, Massimo Fantoni1, Roberto Cauda1
and Simona Di Giambenedetto1
Abstract
Background: Efavirenz (EFV) administration is still controversial for its high rates of interruption mainly related to
central nervous system side effects (CNS-SE). Aim of the study was to define if single tablet regimen (STR) as
compared to bis-in-die (BID) or once-daily (OD) with ≥2 pills-a-day EFV formulations reduced the risk of
interruption.
Methods: Patients starting any cART regimen including EFV + 2NRTIs or switching to EFV + 2NRTIs for simplification
after virological suppression were retrospectively selected. Incidence, probability and prognostic factors of
interruption by different causes were assessed by survival analysis and Cox regression model.
Results: Overall, 553 patients starting EFV-containing regimens were included: 38.2% started BID regimen, 44.5%
OD regimens ≥2 pills and 17.4% STR. The overall proportion of EFV interruption was 37.4% at 4 years; at the same
time point, interruptions for virological failure and toxicity were 8.8% and 16.5% (8% for CNS-SE), respectively.
Starting EFV co-formulated in STR was associated with lower proportion of overall interruption at 4 years
(17.1% vs. 40.6%, p < 0.01). Only one virological failure was observed with STR up to 4 years (1.1% vs. 10.3%
in non-STR, p = 0.051). STR also accounted for lower proportion of interruption by patient decision (1.5% vs. 11.8%,
p = 0.01). No differences of interruption by overall toxicity and CNS-SE were observed. In multivariable analysis, STR
and male gender were associated with lower risk of EFV interruption, while higher CD4 nadir and IDU with higher
risk.
Conclusions: In our experience, starting EFV co-formulated in STR was associated with lower virological failure and
higher adherence, despite a similar proportion of CNS toxicity, thus reducing the risk of treatment interruption.
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Background
Efavirenz (EFV) is a non-nucleoside reverse transcriptase
inhibitor (NNRTI) which has shown good efficacy for the
treatment of HIV infection [1-4]. In combination with a
nucleoside reverse transcriptase (NRTI) backbone, it is
currently recommended as a first line regimen in the
treatment of therapy-naïve patients [5-8]. However, toler-
ability of this drug is still discussed due to potential
toxicity/adverse effects, and in particular central nervous
system side effects (CNS-SE).
It has been demonstrated that a substantial propor-
tion of patients can experience CNS-SE during efavirenz
treatment [9], and frequently CNS-SE can lead to regi-
men discontinuation [10]. Moreover, it has been suggested
that long term treatment with EFV can contribute to
the development of cognitive disorders in HIV-infected
patients [11].
Nonetheless, several EFV characteristics can favor its
large use: EFV has lower pill burden than protease inhibi-
tors (PIs) and, in contrast to integrase inhibitor (InSTI)
currently approved for first line therapy (Raltegravir), it
can be administered once daily (OD). EFV formulation
has been progressively improved during recent years
from 200 mg capsules (which implied assumption of 3
capsules per day) to 600 mg tablets (one tablet OD) [12].
From 2008, EFV is also available in co-formulated shape
with tenofovir and emtricitabine as a single tablet regi-
men (STR) [13]. STR combines a full antiretroviral regi-
men in one tablet taken once daily and this can be
particularly convenient for HIV-infected patients. STR
has demonstrated to improve patients’ satisfaction and
adherence [14]. Finally, costs of EFV-based regimens
are generally lower than those of PI- or InSTI-based
first line regimens and are anticipated to be further
reduced when generic formulations of EFV will be
available.
As a consequence, more data on EFV use in the routine
clinical setting are needed in order to better define the
exact role of this drug in the treatment of HIV infection
subject to its tolerability.
Therefore, aim of this study was to investigate rates and
causes of discontinuation of EFV-based regimens in order
to asses if better drug formulation up to STR reduced the
risk of treatment interruption.
Methods
Patients included
This study included patients attending two clinical ref-
erence centers for HIV treatment in Italy (Catholic
University of the Sacred Heart, Rome; Santa Caterina
Novella Hospital, Galatina, Lecce). All patients signed a
written, informed consent to be included in observa-
tional studies. This informed consent was approved by
the local institutional Ethics Committees.
From the data-bases of the two centers, patients starting
any combined antiretroviral regimen (cART) including
EFV + 2 NRTIs were retrospectively selected from the date
of EFV approval by the European Medicine Agency (1999)
to March 2012. Patients were included in the analysis if
they started an EFV-including cART for the first time
(naïve patients) or switched to EFV + 2 NRTIs regimen
for treatment simplification after virological suppression.
Exclusion criteria were age less than 18 years, prior
administration of mono/dual therapies, prior virological
failure and prior NNRTIs use. Patients who previously
failed treatment but without evidence of genotypic
resistance mutations to any of the drugs in the pre-
scribed regimen containing EFV - according to REGA
rules [15] - were included.
Patients were followed from the time of EFV initiation
(baseline) to discontinuation of the EFV-containing regi-
men or to the last available visit. Demographic, clinical
and laboratory data, including virological and immuno-
logical assessment were collected both from recorded data
and chart review.
Reasons for regimen switch or discontinuation, as re-
ported by the caring physician and aggregated according
to a pre-defined list [16] were collected and recorded in
the database. In particular, our analysis was focused on
the following causes of EFV discontinuation: virological
failure, toxicity, CNS-SE, patient’s decision. Virological
failure was considered a confirmed detectable HIV viral
load (>50 copies/ml) at any point during follow-up.
Statistical analysis
The probability of interruption by virological failure, tox-
icity, CNS-SE, patient’s decision and any cause was esti-
mated by Kaplan Meier curves with log rank test for
assessing differences in strata (e.g. STR compared with
non-STR regimens). Follow-up time was carried out up to
48 months from EFV initiation, since STR containing EFV
was available in Italy from 47 months. Observations were
censored at the time of the last available visit or death,
including patients lost in follow-up, who were classified as
virological failure if the last HIV-RNA was detectable.
Predictors of EFV discontinuation were explored by
means of univariable/multivariable Cox proportional haz-
ard regression. A statistical test was considered significant
if the corresponding p-value was equal or less than 0.05.
Analyses were performed using the IBM SPSS statistical
package v. 20.0 (Armonk, NY; IBM Corp.).
Results
A total of 553 patients starting EFV-containing regimens
were included. Patient’s general characteristics are reported
in Table 1. Of note, the proportion of therapy-naïve and
therapy-switching patients was similar (51.2% vs. 48.8%).
Most subjects switching to EFV + 2 NRTIs were from
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protease inhibitor-based regimen (527, 90.4%); 14 patients
(5.2%) switched from 3 NRTI regimen, 9 (3.3%) from
nevirapine-based regimen and 3 (1.1%) from raltegravir-
based regimen: all subjects switched in order to reduce
the number of pills or frequency of drug administrations.
Overall, 38.2% started BID regimen, 44.5% OD regi-
mens ≥2 pills and 17.4% STR. The most commonly
prescribed NRTIs backbone was tenofovir + emtricitabine/
lamivudine, accounting for more than half of the regi-
mens included, followed by zidovudine + lamivudine;
the combination abacavir + lamivudine had low fre-
quency of prescription.
A total of 161 (29.1%) patients discontinued EFV dur-
ing the 48 months follow up. The number of interrup-
tions, the persons/years of follow-up and the incidence
rates of interruption stratified by type of regimen are re-
ported in Table 2. The rates of interruption were similar
for bis-in-die (BID) and once-daily (OD) ≥2 pills/tablets
regimens, while they were lower for STR.
The main causes of EFV interruption were: CNS toxicity
(n = 37, 6.7%); hypersensitivity (n = 15, 2.7%); metabolic
toxicity (n = 11, 2.2%); other toxicity (n = 14, 2.5%); viro-
logical failure (n = 30, 5.4%); patient wish/non-compliance
(n = 47, 7.9%). One patient died by non-HIV related
causes during follow-up.
By Kaplan-Meier analysis, the estimated probabilities of
EFV interruption were 19.1% at 1 year (95% confidence
intervals, CI: 17.4-20.8) and 37.4% (95% CI: 34.9-39.9) at 4
years. Therapy-naïve patients had a higher probability of
interruption as compared to patients switching therapy:
Table 1 General characteristics of the population included in the study (n = 553)
N. patients (%) Non-STR (n = 457) STR (n = 96) P value
Baseline calendar year
1999–2003 187 (33.8) 187 (40.9) /
2004–2007 181 (32.7) 181 (39.6) /
2008-2012 185 (33.5) 89 (48.1) 96 (100.0)
Age, yearsa 39 (33–45) 38 (33–45) 42 (32–47) 0.06
Male gender 391 (70.7) 324 (70.9) 67 (69.8) 0.83
Non-Italian nationality 130 (23.0) 103 (23.4) 27 (28.1) 0.24
Injecting drug use (as risk factor) 93 (11.4) 57 (12.5) 6 (6.3) 0.08
CDC class C 130 (23.5) 109 (23.9) 21 (21.9) 0.68
Years from HIV diagnosisa 2.6 (0.7-7.4) 2.5 (0.5-7.4) 3.0 (1.4-7.6) 0.09
Naïve 283 (51.2) 248 (54.3) 35 (36.5) 0.002
Number of treatment lines at EFV starta,c 2 (2–3) 3 (2–3) 2 (2–3) 0.17
Baseline Viral Load, log copies/mLa,b 4.8 (4.6-5.2) 4.8 (4.6-5.3) 4.8 (4.1-5.3) 0.35
Nadir CD4 cells count, cells/μLa 196 (93–262) 180 (91–248) 246 (121–326) 0.1
Baseline CD4 cells count, cells/μLa 300 (207–437) 275 (185–433) 430 (322–573) 0.55
Co-administered NRTIs:
TDF + FTC/3TC 315 (57.0) 219 (47.9) 96 (100.0)
ABC + 3TC 21 (3.8) 21 (4.6) /
AZT + 3TC 130 (23.5) 130 (28.5) /
Other 87 (15.7) 87 (19.0) /
Notes: values are expressed as number (percentage), except for amedian (interquartile range); bnaïve patients; cexperienced patients. Bold values are statistically
significant p values.
Abbreviations: BID twice daily, OD once daily, STR single tablet regimens, EFV efavirenz, NRTIs nucleoside reverse transcriptase inhibitors, TDF tenofovir,
FTC emtricitabine, 3TC lamivudine, ABC abacavir, AZT zidovudine: D4T, stavudine.
Table 2 Probability of interruption by any cause by type of regimen started
N. (%) Cumulative interruptions at 48 months (%) Persons/years Incidence rate (95% CI)
Overall 553 (100.0) 161 (29.1) 12927 1.25 (1.07-1.45)
Bis-in-die (BID) 211 (38.2) 83 (39.3) 5939 1.40 (1.13-1.73)
Once-daily (OD) >2 pills 77 (13.9) 22 (28.6) 1640 1.34 (0.89-2.02)
Once daily (OD) 2 pills 169 (30.6) 42 (24.9) 3158 1.33 (0.99-1.79)
Single tablet regimen (STR) 96 (17.4) 14 (14.6) 2190 0.64 (0.38-1.07)
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43.9% (95% CI: 40.3-47.5) vs. 30.0% (95% CI: 26.6-33.4) at
4 years (p = 0.013). Probabilities of interruptions for viro-
logical failure were 2.8% (95% CI: 2.0-3.6) and 8.8% (95%
CI: 7.0-10.6), whilst those for toxicity were 10.2% (95% CI:
8.9-11.5) and 16.5% (95% CI: 14.5-18.5) at 1 and 4 years,
respectively. CNS-SE accounted for about a half of inter-
ruptions for toxicity: 5.7% (95% CI: 4.6-6.8) and 8.0% (95%
CI: 6.7-9.3), respectively. CNS-SE interruptions were gen-
erally observed in the first months of EFV use (only one
interruption for CNS-SE was observed after the first 24
months). Probability of interruption for personal patient
decision was 4.9% (95% CI 3.9-5.9) at 1 year and 10.3%
(95% CI: 8.5%-12.1%) at 4 years.
Figure 1a-f reports the survival analysis comparing STR
vs. non-STR, stratified by reason of interruption. While
no significant differences were observed comparing OD
vs. BID regimens ≥2 pills/tablets (Figure 1a), STR were
associated with a significant lower probability of overall
interruption at 4 years: 14/96, 17.1% by Kaplan-Meier es-
timation (95% CI: 12.8-21.4) vs.147/457, 40.6% (95% CI:
37.9-43.3), p < 0.01 (Figure 1b). Only one virological fail-
ure (vs. 26) was observed with STR up to 4 years: 1.1%
(95% CI: 0.0-2.2) vs. 10.3% (95% CI: 7.7-12.9), p = 0.051
(Figure 1c). No differences of interruption by overall tox-
icity and a higher, though non-significant, frequency of
interruption by CNS-SE related to STR was observed
(Figure 1d-e). In contrast, STR accounted for significant
lower proportion of interruption by patient decision: 1 in
STR patients (1.5%, 95% CI: 0.0-3.0) vs. 36 (11.8%, 95%
CI: 9.8-13.8), (Figure 1f ).
Table 3 reports the crude (univariable) and adjusted
(multivariable) hazard ratios (HR) from fitting Cox regres-
sion for treatment interruption by any cause. At adjusted
analysis STR and male gender were associated with lower
risk of EFV interruption while intravenous drug use (IDU)
as risk factor and higher CD4 nadir showed a higher risk.
The association of interruption with higher CD4 nadir
was detected, after adjustment in experienced patients
(HR: 1.09, 95% CI: 1.02-1.18, p = 0.022) and not in naïve
patients (HR: 1.03, 95% CI: 0.94-1.12, p = 0.54).
Age was not associated with treatment interruption,
even taking into account subgroups of patients: i.e. older
age (>50 years) was not associated with EFV interruption.
We also performed different sets of sensitivity analyses
in order to better account for the imbalance in some
characteristics of the two groups at baseline. Excluding
patients not treated with a tenofovir-containing back-
bone and then comparing STR vs. OD-2 pills regimens
(tenofovir/emtricitabine as backbone) (249 patients), a
lower proportion of treatment interruption in STR
group was detected (17.1% vs 34.7%, p = 0.022) at sur-
vival analysis. Moreover, excluding patients with IDU as
risk factor (490 patients), a lower proportion of interrup-
tion was also detected (15.3% vs. 37.9%, p = 0.005) and
finally, taking into account patients starting EFV-
containing regimen from 2007 (since STR was available
in Italy, 213 patients), still a significant lower proportion
of interruption was observed (17.1% vs 34.1%, p = 0.03).
Discussion
EFV has been available for clinical use for many years
and there is a large experience with the drug administra-
tion in clinical practice. However, studying EFV and its
formulation history is still of clinical relevance, because
of complex mechanics of tolerability and side effects, and
also because its patent is next to expire. A recent study
focused on the high risk of EFV interruption, mainly
related to CNS-SE [17], but there is a lack of comprehen-
sive works.
Our data showed that the probability of EFV interrup-
tion (nearly 30% after 48 months) was similar to that
observed in Italy at the beginning of the EFV availability
[18]. However, we also observed that the improved EFV
formulation had a positive effect on the risk of interrup-
tion. In particular, the effect was minimal and not statisti-
cally significant when moving from BID to OD regimens
or reducing the number of pills/tablets up to 2 within
OD regimens. Conversely, the real significant improve-
ment was observed when taking into account STR, which
demonstrated a clear advantage also compared to 2 pills
regimens.
The greatest improvement in the risk of interruption
related to STR was evident when considering virological
failure and personal patient decision as reasons of inter-
ruption, suggesting in both cases an improvement in pa-
tients’ adherence. The adherence improvement related to
the switch from various types of regimens to STR had
already been described [19], leading to a lower probability
of virological failure [20]. A clear improvement in adher-
ence and quality of life related to the switch to STR in pa-
tients previously treated with OD regimens containing
EFV has been suggested [21].
Our data also demonstrated that the use of STR was
not associated with lower probability of interruption for
CNS-SE and that patients preferred the simplest regi-
men in spite of non-apparent differences in toxicity.
These results are interesting in light of the expiration
of EFV patent in 2013, as well as that of other antiretro-
viral drugs (e.g. lamivudine, abacavir), considered a favor-
able circumstance to exploit the development of generic
antiretroviral drugs to reduce costs [22].
The use of generic drugs may have as consequence rele-
vant changes in formulations, such as the reversion from
STR to ≥2 pills/tablets combination. Possible consequences
of losing STR in terms of adherence and treatment success
have been already focused [23]. It is therefore important to
emphasize that this choice must be evaluated in light of its
real cost-effectiveness, taking into account the increased
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Figure 1 a-f: Kaplan-Meier plots estimating probability of treatment interruption for specific reasons stratified by STR vs. no-STR.
Notes: (1a) overall probability of interruption by type of regimen; (1b) overall probability of interruption STR vs. no STR; (1c) probability of
interruption by virological failure STR vs. no STR; (1d) probability of interruption by any side effect STR vs. no STR; (1e) probability of interruption
by central nervous system side effects STR vs. no STR; (1f) probability of interruption by personal decision STR vs. no STR.
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risk of interruption and virological failure. Our findings
demonstrate that starting regimens with a higher pill bur-
den can be associated with a higher risk of treatment
interruption, mainly related to adherence, and thus sug-
gesting the benefit of maintaining STR. However, it should
also be emphasized that not all patients tolerating well a
STR will be certainly less adherent or will interrupt treat-
ment after switching to a regimen with the same drugs,
not co-formulated. The choice of the regimen should be
tailored on individual patients, discussing benefit and
potential risk of each decision.
In our analysis higher CD4 nadir was associated with
higher risk of interruption. This association was detected
only in the multivariable analysis, and can be interpreted
with higher adherence in patients who achieved lower
CD4 level, in particular experienced patients, in whom a
low CD4 nadir at baseline was observed.
We acknowledge that our study can have some limita-
tions because uncontrolled biases can occur in retrospect-
ive studies; however, reasons for regimen switch or
discontinuation were reported by the caring physician and
aggregated according to a pre-defined list at the time of
occurrence, similarly to other large observational multi-
center databases. The two groups of patients (STR and
non-STR) were not completely matched for all character-
istics at baseline; in particular, a higher proportion of naïve
patients and a higher, despite not significant, percentage
of IDU was observed in the non STR group. This could
have partly influenced the results; however, all these vari-
ables were adjustment factors in the multivariable model
and several subgroup sensitivity analysis were performed
to account for this potential bias. Another potential limita-
tion of the present analysis may be related to differences
in regimens prescribed by calendar year. Indeed, STR was
approved in Italy from 2008, but non-STR regimens are
currently prescribed when starting an EFV-containing
regimen. However, in our analysis, calendar year, IDU and
CD4 count/CD4 nadir were used as adjustment factors to
correct this possible bias.
Conclusions
In conclusion, our results demonstrated that starting
EFV co-formulated in STR was associated with lower
hazard of virological failure and with higher adherence as
compared to other formulations (i.e. BID or ≥2 pills OD),
despite keeping similar toxicity profiles and in particular
CNS toxicity, with subsequent lower risk of overall treat-
ment interruption.
Abbreviations
STR: Single tablet regimen.
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